28/01/2025 – Presentation of the AB Science webcast held on January 28, 2025 Download PDF Category: 2025By Alexis BERNARD29 January 2025 Partager cet article Share on LinkedInShare on LinkedIn Share on XShare on X Share on FacebookShare on Facebook Share on WhatsAppShare on WhatsApp Pin itShare on Pinterest Author: Alexis BERNARD Post navigationPreviousPrevious post:Live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CETNextNext post:Summary of the webcast held on January 28, 2025Related PostsAB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 204022 December 2025AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share18 December 2025AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025AB Science announces the successful completion of a 2.8 million euros private placement17 October 2025Summary of the virtual conference held on October 16, 202516 October 2025
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 204022 December 2025
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share18 December 2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers15 December 2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function11 December 2025
AB Science announces the successful completion of a 2.8 million euros private placement17 October 2025
